A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity

• DOI: 10.1186/s12879-017-2259-2
• Publication Date: 2017-02-20T07:46:46Z
• Authors: Andrea M. Teng; Giorgi Kvizhinadze; Nisha Nair; Melissa McLeod; Nick Wilson; Tony Blakely
• Keywords: Cancer screening

The World Health Organization recommends all countries consider screening for H. pylori to prevent gastric cancer. We therefore aimed estimate the cost-effectiveness of a serology-based program in New Zealand, country that includes population groups with relatively high cancer rates. A Markov model was developed using life-tables and morbidity data from national burden disease study. modelled reduced incidence non-cardia attributable pylori, if infection identified by serology screening, expected be reached program. health system perspective taken detailed individual-level costing used. For adults aged 25–69 years old, nation-wide found have an incremental cost US$196 million (95% uncertainty interval [95% UI]: $182–$211 million) gains 14,200 QALYs UI: 5,100–26,300). Cost per QALY gained US$16,500 ($7,600–$38,400) total 17% (6%-29%) future cases could averted lifetime follow-up. targeted Māori only (indigenous population), more cost-effective at US$8,000 ($3,800–$18,500) QALY. This modeling study likely this high-income country, particularly indigenous population. While further research is needed help clarify precise benefits, costs adverse effects such programs, there seems reasonable case policy-makers give pilot programs consideration, any elevated rates